Checkmate 143, the first phase 3 randomized clinical trial evaluating the efficacy of adjuvant PD-1 blockade in glioblastoma using nivolumab, concluded that it did not improve overall survival compared to anti-VEGF therapy with bevacizumab (156). This evidence concerns the gene VEGFA and glioblastoma.